P 1736
Alternative Names: P1736; P1736-05Latest Information Update: 11 Jun 2015
At a glance
- Originator Piramal Life Sciences
- Developer Piramal Enterprises
- Class Antihyperglycaemics
- Mechanism of Action Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 13 May 2008 Phase-I clinical trials in Type-2 diabetes mellitus in Netherlands (PO)